A diagnosis not to be missed: Nonclassic steroid 11β-hydroxylase deficiency presenting with premature adrenarche and hirsutism

Abstract

Context: Steroid 11β-hydroxylase (CYP11B1) deficiency (11 OHD) is the second most common form of congenital adrenal hyperplasia. Milder nonclassic forms are rare and at risk to be missed. Objective: The objective of the study was to demonstrate the challenges in diagnosing nonclassic 11 OHD. Patients and Methods: Patient 1, a 10-year-old boy, presented with high-normal blood pressure and previously unexplained exaggerated adrenarche from age 4 years. Previous tests at the age of 8 years showed normal 17-hydroxyprogesterone concentrations with increased androgens. Patient 2, a 14-year-old female, presented with facial hirsutism, primary amenorrhea, and high-normal blood pressure. Novel CYP11B1 mutations were functionally analyzed in transiently transfected COS7 cells measuring the conversion of 11-deoxycortisol to cortisol by liquid chromatography-tandem mass spectrometry. Results: Biochemical findings including urinary steroid metabolite analysis by gas chromatography-mass spectrometry were suggestive of 11 OHD in all patients. CYP11B1 mutation analysis revealed compound heterozygosity in patient 1 (g.235T>;A, p.F79I/g.2608C>;T, p.R138C) and a homozygous mutation in patient 2 and two siblings (g.2623C>;T, p.R143W). Functional in vitro analysis demonstrated partially impaired CYP11B1 activity compared with wild-type (p.F79I: 8.8% ± 0.8% (SEM); p.R138C: 9.8% ± 0.8%; p.R143W: 10.6% ± 1.2%). Conclusion: In addition to nonclassic 21-hydroxylase deficiency and steroid-secreting tumors, non-classic 11 OHD should be considered as an important differential diagnosis in patients with unexplained hyperandrogenism without 46, XX disorder of sex development. Nonclassic 11 OHD is likely to be missed when relying on measuring standard steroid hormone panels. This diagnosis needs to be established early in life to avoid long-term health problems such as short stature, hyperandro-genism-related metabolic complications, potentially severe arterial hypertension, and cardiovascular consequences. Copyright © 2013 by The Endocrine Society.